Sir Greg Winter
Non-Executive Director & Chairman
Pharma
Biosceptre
United States of America
Biography
Greg is Master of Trinity College Cambridge and has served the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) as a Head of Division, Deputy Director and Acting Director. His scientific career has been based almost entirely in Cambridge where his work included protein sequencing and nucleic acid sequencing. He later developed technologies for making humanised antibodies and also for making human antibodies in bacteria. Most of the therapeutic antibodies on the market today have been developed using methods devised by him.
Research Interest
Greg was a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology.